We investigated the prevalence of germline BRCA mutations in a population-based cohort of Austrian women diagnosed with ovarian cancer and its association with family history of cancer. We prospectively collected family pedigrees of 443 Austrian ovarian cancer patients who had been tested for the presence of a germline BRCA or 2 mutations and correlated the familial breast and ovarian cancer burden with the prevalence of BRCA mutations and disease onset. The probability of carrying a gBRCA mutation in patients without family history of cancer is 14% (95% CI 9%-22%), as opposed to 45% (95% CI 31%-59%) of patients with at least one family member with ovarian cancer, and 47% (95% CI 40%-54%) if other relatives have developed breast cancer. If both breast and ovarian cancer are diagnosed in the family, the probability of carrying a germline BRCA1 or 2 mutations is 60% (95% CI 50%-68%). germline BRCA1 or mutations in families with ovarian cancer only are commonly located in the Ovarian Cancer Cluster Regions when compared to families with both breast and ovarian cancer (P = 0.001, and P = 0.020, respectively). While gBRCA mutation carriers with ovarian cancer do not have a significantly different age at onset than patients with a family history of cancer, gBRCA1 carriers in general have an earlier onset than gBRCA2 carriers (P = 0.002) and patients without a mutation (P = 0.006). The rate of germline BRCA1 or 2 mutations in ovarian cancer patients without a family history or breast or ovarian cancer is low. However, in women with additional family members affected, the prevalence is considerably higher than previously reported.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6488144 | PMC |
http://dx.doi.org/10.1002/cam4.2000 | DOI Listing |
CA Cancer J Clin
January 2025
Division of Medical Oncology, Department of Internal Medicine, Huntsman Cancer Institute, University of Utah, Salt Lake City, Utah, USA.
Poly(adenosine diphosphate ribose) polymerase (PARP) inhibitors, such as olaparib, talazoparib, rucaparib, and niraparib, comprise a therapeutic class that targets PARP proteins involved in DNA repair. Cancer cells with homologous recombination repair defects, particularly BRCA alterations, display enhanced sensitivity to these agents because of synthetic lethality induced by PARP inhibitors. These agents have significantly improved survival outcomes across various malignancies, initially gaining regulatory approval in ovarian cancer and subsequently in breast, pancreatic, and prostate cancers in different indications.
View Article and Find Full Text PDFCurr Mol Med
January 2025
Department of Gynaecology and Obstetrics, The First Affiliated Hospital of Ningbo University, No.59 Liuting Street, Haishu District, Ningbo City, Zhejiang Province, 315010, China.
Background: Ovarian cancer is one of the deadliest gynecologic cancers, with chemotherapy resistance as the greatest clinical challenge. Autophagy occurrence is associated with cisplatin (DDP)-resistant ovarian cancer cells. Herein, the role and mechanism of alpha-synuclein (SNCA), the autophagy-related gene, in DDP resistance of ovarian cancer cells are explored.
View Article and Find Full Text PDFJ Family Med Prim Care
December 2024
Histopathology, Department of Pathology, Rajendra Institute of Medical Sciences, Ranchi, Jharkhand, India.
Background: Ovarian tumors are the most prevalent neoplasms worldwide, affecting women of all ages. According to Globocan's 2022 projections, by 2050, the number of women diagnosed with ovarian cancer worldwide will increase by over 55% to 503,448. The number of women dying from ovarian cancer is projected to increase to 350,956 each year, an increase of almost 70% from 2022.
View Article and Find Full Text PDFToxicol Res (Camb)
January 2025
Department of Obstetrics and Gynecology, Jinggangshan University Clinical School of Medicine, No. 28 Xueyuan Road, Ji'an, Jiangxi 343000, China.
Ovarian cancer (OC) is a significant cause of cancer-related mortality among women. This study explores the efficacy of L. () extract, known for its phytoestrogenic properties, in treating OC through hormonal and metabolic modulation.
View Article and Find Full Text PDFPostgrad Med J
January 2025
Institute of Public Health, College of Medicine, National Yang Ming Chiao Tung University, Yang Ming Campus, No. 155, Sec. 2, Linong Street, Beitou District, Taipei 11217, Taiwan.
Background: Thyroid cancer primarily affects young women and raises concerns about future fertility due to treatments of thyroidectomy and radioactive iodine (RAI) therapy. This study investigated the effects of these treatments on pregnancy probability in young female patients post-diagnosis.
Methods: A nationwide, population-based study using data from Taiwan's National Health Insurance Research Database (2000-2017) examined pregnancy likelihood in women ≤45 years with thyroid cancer.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!